SRC and cancer: Our data show that expression of FGFR3-TACC3 and S249C results in a paradoxical resistance to dasatinib despite the constitutive activation of the Src pathway, reinforcing the idea that this drug as a monotherapy is likely to be ineffective in cancers with these FGFR3 molecular alterations.